Too often, the disconnect between a company’s IT department and its business teams slows progress and leads to missed ...

Potent Antiviral Activity in Preclinical Challenge Model: Results from a rodent challenge model showed that 100% of mice ...

ARS Pharmaceuticals, Inc.'s stock soared 25% on strong earnings. Learn about neffy's market potential, risks, and future ...

Poster underscores Tivoxavir Marboxil's potential for the treatment of bird flu, supported by 100% survival in a rodent challenge model, potent suppression of resistant viruses and Phase 1 dataFull da ...

With the popular social media app once again at risk of going dark, there are best practices pharma brands can use on other ...

Drugmakers are urging the Trump administration and European Union officials to exclude medical goods from expanding tariff ...

Pharma companies must balance HCP access and MHRA/ABPI compliance by preventing public search indexing of promotional ...

According to Benzinga Pro, Royalty Pharma's peer group average for short interest as a percentage of float is 4.00%, which ...

Arrowhead's ARO-C3 cut C3 levels by up to 89% and proteinuria by 41% in a Phase 1/2 trial. Additional results will be ...

Here is how Atyr Pharma (ATYR) and Delcath Systems, Inc. (DCTH) have performed compared to their sector so far this year.

New treatment paradigms are making biopharma industry stakeholder communications more ambitious and complex. But they must ...

Brand.com’s are connecting HCPs to information, with fewer hoops to jump through, courtesy of new digital tools promising to ...